Direct compression is selected as a nonaqueous solid-dose route because the hydrochloride salt of 1-(4,5-dihydro-2-thiazolyl)-3-azetidinethiol contains a free thiol that is susceptible to oxidative dimerization, metal-catalyzed degradation, and moisture-induced instability during wet massing. The API is screened through a 250 μm sieve under USP <786> particle size distribution methodology and then dry-mixed with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide using a 1:9 active-to-excipient preblend before final dilution to the intended label claim. Blend uniformity is monitored under USP <905>, and tablet content uniformity is verified by the same chapter. Dissolution is evaluated according to USP <711> using Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid where solubility permits. Compression is executed on a rotary tablet press with 10 kN to 20 kN precompression force, although the final compression range must be qualified for this specific thiol-bearing molecule because punch contact with metal surfaces may promote oxidation. Lubricant selection requires a compatibility assessment; magnesium stearate is not automatically preferred because residual metal ions and hydrophobic films can interfere with the thiol group. Sodium stearyl fumarate at 0.5% w/w to 1.0% w/w is a common alternative starting range in direct compression development. The finished uncoated tablet core is tested for hardness, friability under USP <1216>, and disintegration under USP <701>. Moisture content in the API is measured by USP <921>; free water present above 0.5% w/w may shorten the oxidative induction period. Published data for this specific configuration is limited, so the allowable moisture limit should be established by ICH Q1A and ICH Q1B forced degradation studies.

What Limits Capsule Filling Speed on Automated Dosator Machines?

Powder flow from the hopper into a dosator or tamping pin station is described by the Carr index and Hausner ratio derived from USP <616> bulk density and tapped density. When the direct compression blend contains a high proportion of the azetidinethiol hydrochloride with plate-like or acicular particles, flow from the hopper becomes the primary rate-limiting factor on a Zanasi or MG2 dosator capsule filler. The blend is dry-mixed with 0.5% w/w colloidal silicon dioxide and 0.5% w/w sodium stearyl fumarate; the optimal glidant concentration is determined by shear cell measurements according to ASTM D6128-16. The filled capsule weight is monitored to reject units outside ±3% of target mass. Segregation potential is tested by sampling the powder bed at hopper start, middle, and end under USP <905> blend uniformity conditions. Capsule shells composed of gelatin or hydroxypropyl methylcellulose have different moisture contents; type B gelatin shells contain 13% w/w to 16% w/w water, which can transfer to a hygroscopic hydrochloride API during long dwell times. For this reason, low-moisture hydroxypropyl methylcellulose capsules or gelatin capsules equilibrated at 35% RH to 45% RH are alternative packaging configurations. Automated filling speed is typically reduced to 30% to 60% of maximum rated equipment output until lock hopper humidity is maintained below 40% RH; the exact reduction factor must be qualified on the installed filler. Empty capsule shells are tested under USP <701> disintegration and USP <671> moisture vapor transmission rate where applicable. The resulting terminal product is a hard capsule for oral administration, with release testing based on fill weight, content uniformity, and dissolution.

In high-humidity packaging zones, hard gelatin capsule products may require an additional banding or sealing operation because moisture ingress through the capsule body-cap junction accelerates degradation of a free thiol. The banding process applies an aqueous gelatin or hydroxypropyl methylcellulose solution at 45 °C to 55 °C around the cap-body seam; the capsule is then rotated and dried under controlled air at 25 °C to 30 °C. Although the banding step itself introduces water, the subsequent drying phase reduces the shell moisture back to the initial specification. The terminal capsule is packed in aluminum-PVC/PVDC blisters with a silica gel desiccant canister; moisture uptake is monitored under USP <671>. The desiccant quantity is calculated from the package moisture vapor transmission rate and the sorption isotherm of the capsule shell. The sealing operation may also reduce oxygen permeability because the band forms a continuous barrier at the seam. Packaging qualification follows 21 CFR 211.94 and 21 CFR 211.166; stability batches are stored at 25 °C/60% RH and 40 °C/75% RH as specified in ICH Q1A. Published data for this specific thiazolidine derivative in banded hard capsules is limited; therefore the seal integrity test method should be correlated with content uniformity and related substances.

Granule Production Requires Moisture Control Below the Monohydrate Transition Threshold

Because the API contains a free thiol, wet granulation with aqueous binder is not the preferred route for granulated oral dosage forms. When granules are needed for sachet filling or tablet recompression, dry granulation by roller compaction is selected. The blend is pre-granulated with 1.5% w/w to 3.0% w/w hydroxypropylcellulose as dry binder and 0.5% w/w colloidal silicon dioxide; the mixture is passed through a roller compactor at 5 kN/cm to 10 kN/cm roll force and 2 rpm to 4 rpm roll speed, followed by an oscillating mill with an 800 μm screen. The granules are evaluated for tapped density by USP <616>, flowability by USP <1174>, and particle size by USP <786>. The moisture content of the granules is maintained below 0.5% w/w by dry granulation and by controlling the process room at 30% RH to 40% RH; this limit must be confirmed by forced degradation studies. Granule-filled sachets are sealed under nitrogen to reduce headspace oxygen. The resulting terminal product is a single-dose oral granule for direct administration or reconstitution. Because the thiol functionality may bind to metal ions in packaging or equipment, contact surfaces made of 316L stainless steel with passivation are recommended; leachable testing follows USP <1664> and ICH Q3D for elemental impurities.

For the injectable lyophilized presentation, the hydrochloride salt is dissolved in Water for Injection at a concentration of 10 mg/mL to 50 mg/mL based on the target unit dose; the actual concentration depends on the approved label and is validated by process characterization. The drug solution is compounded under a nitrogen-purged vessel to keep dissolved oxygen below 0.5 ppm; the solution is filtered through a 0.22 μm polyvinylidene fluoride membrane and filled into Type I borosilicate glass vials under ISO 14644-1 ISO 5 conditions. Mannitol or sucrose at 4.0% w/v to 5.0% w/v is commonly evaluated as a crystalline or amorphous bulking agent to provide cake structure. The vials are partially stoppered and lyophilized with primary drying at −30 °C to −20 °C shelf temperature and secondary drying at 25 °C to 40 °C; the cycle is qualified to yield a moisture content below 0.5% w/w by USP <921>. The headspace is backfilled with nitrogen to 99.0% purity before final stoppering. Sterility testing per USP <71>, bacterial endotoxin testing per USP <85>, particulate matter per USP <788>, and container closure integrity per USP <1207> are mandatory release tests. Published data for this specific configuration is limited; filter adsorption and cake collapse must be evaluated during formulation and process development.

When Terminal Sterilization Is Not Feasible for Thiol-Bearing Injectable Formulations

Terminal moist-heat sterilization at 121 °C for 15 minutes is the default regulatory expectation for parenteral drug products under 21 CFR 211.113 and EU GMP Annex 1 section 8.25. However, autoclaving a thiol-containing azetidine hydrochloride may induce hydrolysis, disulfide formation, and loss of assay due to the aqueous environment and saturated steam condensate. For this reason the injection is produced by aseptic filtration into sterilized vials, with each batch supported by media fill simulation under EU GMP Annex 1 section 9.39. The bulk solution is prepared in a closed stainless steel or disposable compounding system, then sparged with nitrogen to maintain dissolved oxygen below 0.5 ppm; the solution is filtered through a 0.22 μm sterilizing-grade membrane and filled under ISO 5 unidirectional airflow. The use of stainless steel must be balanced against the potential for thiol binding to trace iron or nickel from the vessel surface; passivated 316L stainless steel or single-use polymer bags are alternative contact materials. The final sterile solution or lyophilized product is tested for sterility by USP <71>, endotoxin by USP <85>, and visible and subvisible particles by USP <788>. The container closure system is qualified under USP <1207>. Published data for this specific API under steam sterilization is limited; if terminal sterilization is pursued, the thermal degradation profile must be compared with aseptic manufacture in a formal process risk assessment.

Tablet Film Coating and Aqueous Barrier Selection

Film coating of the direct-compressed tablet is adopted when taste masking, light protection, or humidity protection is required. Aqueous coating of a thiol-containing core is approached with caution because water spray can accelerate surface degradation and induce tablet softening. A polyvinyl alcohol-based or hydroxypropyl methylcellulose-based system at 10% w/w to 12% w/w solids in purified water is sprayed at an inlet air temperature of 60 °C to 70 °C and a product bed temperature of 38 °C to 42 °C. The film thickness target is 3% w/w to 4% w/w weight gain. Process dwell time is limited because the moist surface remains in contact with the thiol API for the duration of spraying and drying. Alternatively, dry coating technologies such as electrostatic powder coating may be evaluated if aqueous exposure is unacceptable. The film-coated tablet is tested for disintegration by USP <701> and dissolution by USP <711>. The coating suspension must be prepared under 21 CFR 211.67 and 21 CFR 211.80 for equipment and component control. The use of metal-oxide opacifiers such as iron oxide should be avoided or justified by compatibility testing because thiol groups are known to coordinate transition metals; published data for this specific API is limited.